Browse the evidence

Tirzepatide administered once weekly produces significant weight loss (mean difference -16.32% body weight) and improves cardiometabolic markers (BMI, waist circumference, lipids, blood pressure) in patients with overweight or obesity without diabetes mellitus, though it carries a significantly elevated risk of gastrointestinal side effects.

For individuals with overweight or obesity without diabetes, tirzepatide is a highly effective pharmacological intervention for weight loss, producing greater reductions than GLP-1 RAs like semaglutide. It also improves blood pressure, lipids, and glycemic control. However, patients must be prepared for a high likelihood of gastrointestinal side effects (nausea, vomiting, diarrhea), which can lead to discontinuation. The overall risk of serious adverse events is not significantly higher than placebo, but the burden of GI symptoms is a key consideration for adherence.

GLP-1 receptor agonists significantly increase the likelihood of achieving weight loss compared to placebo, with tirzepatide and semaglutide demonstrating the highest relative efficacy among evaluated agents.

If you have obesity or overweight with related health issues, GLP-1 receptor agonists like semaglutide or tirzepatide are highly effective pharmacological options. They work by mimicking a hormone that reduces hunger and slows digestion. Clinical data shows they significantly increase the chance of losing weight compared to placebo, with tirzepatide and semaglutide showing the best results. These medications are FDA-approved for chronic weight management and should be used in combination with lifestyle changes.

For patients with type 2 diabetes and chronic kidney disease (CKD), SGLT2 inhibitors are recommended to reduce CKD progression, with GLP-1 receptor agonists as an alternative if SGLT2 inhibitors are contraindicated.

If you have diabetes and kidney disease, ask your doctor about SGLT2 inhibitors (like empagliflozin) or GLP-1 agonists (like liraglutide). These drugs have been proven to slow down kidney damage and reduce the risk of needing dialysis, offering benefits beyond just lowering blood sugar.

Excess visceral adipose tissue (VAT) is an independent risk factor for cardiovascular disease and mortality, regardless of overall body mass index (BMI).

Focus on waist circumference, not just weight. If your waist is large, your visceral fat is likely high, which drives heart disease risk even if your BMI is normal. Measure your waist and aim to reduce it through lifestyle changes.

Adherence to the Mediterranean Diet (MedDiet) significantly reduces the incidence of cardiovascular disease (CVD), including myocardial infarction, stroke, and cardiovascular mortality, in both primary and secondary prevention populations.

Adopt a Mediterranean-style eating pattern as your primary dietary strategy for heart health. Prioritize extra-virgin olive oil as your main fat source, consume plenty of vegetables, fruits, legumes, and nuts, and include moderate amounts of fish and poultry. If you are at high risk for heart disease, this pattern has been shown in large trials to significantly reduce the risk of heart attack and stroke compared to standard low-fat advice.

Once-weekly semaglutide 2.4 mg delivers significant weight loss (approx. 15-16% in non-diabetics, 9.6% in diabetics) and improves cardiovascular risk factors, and is FDA-approved for chronic weight management in adults with BMI ≥30 kg/m2 or ≥25 kg/m2 with comorbidities.

If you have type 2 diabetes and struggle with weight, once-weekly semaglutide 2.4 mg is a highly effective, FDA-approved option. It can lead to nearly 10% body weight loss when combined with lifestyle changes. While you may experience some gastrointestinal side effects, most people tolerate it well enough to stay on the medication, which is crucial for maintaining the weight loss and improving heart health markers.

Modest weight loss (5-10%) prevents type 2 diabetes in high-risk individuals, while greater weight loss (>10-15%) can induce remission of established type 2 diabetes, particularly when intervention occurs early in the disease course.

If you have prediabetes or early type 2 diabetes, losing just 5-10% of your body weight can significantly lower your risk of developing full-blown diabetes. If you already have diabetes, losing more weight (10-15%) can potentially put the disease into remission, especially if you act early. Focus on sustainable weight loss through diet, medication, or surgery as advised by your doctor, rather than just managing blood sugar with pills alone.

Obesity is a multisystem disease where excess adiposity causes comorbidities across multiple organ systems (cardiovascular, metabolic, malignancy, mental health), and weight loss can prevent or reverse many of these conditions.

Obesity is a serious medical condition affecting your heart, liver, brain, and risk of cancer, not just your appearance. Treating it with weight loss can prevent or reverse many of these health issues. Seek medical help for obesity as you would for any other chronic disease.

Replacing saturated fatty acids (SFA) with polyunsaturated fatty acids (PUFA) or whole grains reduces cardiovascular disease (CVD) risk, whereas replacing SFA with refined carbohydrates does not reduce risk and may increase it.

To lower your heart disease risk, do not just cut saturated fats (found in butter, cheese, fatty meats). You must replace them with the right things. Swap them for unsaturated fats (like olive oil, nuts) or whole grains (oats, brown rice). Avoid replacing them with refined carbohydrates (white bread, sugar), as this does not lower risk and may increase it. Plant proteins are also a beneficial replacement option.

Bariatric-metabolic surgery (Roux-en-Y gastric bypass or sleeve gastrectomy) significantly increases the probability of histological NASH resolution without worsening fibrosis compared to lifestyle modification plus best medical care in patients with obesity and NASH.

For individuals with obesity and confirmed NASH, bariatric surgery (Roux-en-Y or sleeve gastrectomy) is a highly effective treatment for resolving liver inflammation and fibrosis, far outperforming lifestyle changes and medical therapy alone. This should be considered a primary treatment option for eligible patients.

Adhering to a cluster of ideal lifestyle practices (regular physical activity, sound nutrition, weight management, and tobacco avoidance) reduces the risk of cardiovascular disease by more than 80% and diabetes by more than 90%.

To drastically lower your risk of heart disease and diabetes, focus on four core daily habits: move moderately for at least 150 minutes a week, eat a diet rich in plants and whole grains, maintain a healthy weight, and do not smoke. You do not need to be perfect; even small improvements in these areas yield significant health benefits.

Smoking cessation significantly reduces the risk of cardiovascular disease and stroke, with substantial benefits accruing over a very brief period of time.

If you smoke, quitting is one of the most impactful things you can do for your heart health. The benefits start quickly, so seek support through counseling or medications to help you quit.

GLP-1 receptor agonists (GLP-1 RAs) promote significant, sustained weight loss in adults with obesity (BMI ≥30 kg/m2) or overweight (BMI ≥27 kg/m2) with comorbidities, primarily through central nervous system-mediated appetite suppression and reduced caloric intake, with efficacy superior to previously approved anti-obesity medications.

GLP-1 agonists like semaglutide and liraglutide are FDA-approved for chronic weight management in adults with obesity or overweight with comorbidities. They work by targeting hormonal pathways in the brain to reduce hunger and increase satiety, leading to significant, sustained weight loss that is roughly double that of older medications. Treatment is available in daily or weekly injectable forms, as well as oral tablets, and is intended for long-term use to maintain results without the 'Yo-Yo' effect common with short-term diets.

Adherence to a Mediterranean diet (MedDiet) is associated with reduced body weight, lower BMI, and a decreased risk of incident overweight or obesity compared to control diets or low-adherence groups.

Adopt a Mediterranean-style eating pattern as your default. Focus on daily consumption of vegetables, fruits, whole grains, legumes, nuts, and olive oil. Eat fish 2-3 times a week and limit red/processed meats and sweets. You do not need to count calories strictly, but prioritize whole, minimally processed foods. This approach is sustainable, tasty, and has strong evidence for preventing weight gain and obesity.

GLP-1 receptor agonists (specifically semaglutide 2.4 mg weekly and liraglutide 3.0 mg daily) produce significant weight loss in adults with obesity without diabetes, with semaglutide demonstrating superior efficacy compared to liraglutide.

For adults with obesity without diabetes, GLP-1 receptor agonists like semaglutide (2.4 mg weekly) and liraglutide (3.0 mg daily) are effective weight loss treatments. Semaglutide offers greater weight reduction than liraglutide. These drugs work by mimicking a hormone that increases satiety and slows digestion. Common side effects include gastrointestinal issues, which are often managed by starting with a lower dose and gradually increasing it.

GLP-1 receptor agonists (GLP-1 RAs) such as semaglutide and liraglutide produce significant, sustained weight reduction in adults with obesity by acting on the gut-brain axis to reduce appetite and food intake.

Semaglutide 2.4 mg injected once weekly, combined with lifestyle counseling, leads to an average 14.9% body weight loss in adults with obesity over 68 weeks. Side effects like nausea are common initially but typically subside; starting with a lower dose helps manage this.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, produces greater weight reduction than GLP-1 monotherapy in individuals with obesity without type 2 diabetes.

Tirzepatide 15 mg injected once weekly leads to an average 20.9% body weight loss in adults with obesity without diabetes over 72 weeks. This dual-action hormone therapy is more effective than GLP-1 monotherapy.

Adherence to a diet high in fruit, vegetables, nuts, legumes, fish, and whole-fat dairy is associated with significantly lower all-cause mortality and cardiovascular disease risk across diverse global populations, particularly in lower-income countries.

Focus your daily diet on increasing the intake of six specific food groups: fruits, vegetables, legumes, nuts, fish, and whole-fat dairy. Aim to consume these foods in amounts that exceed the median intake of your local population. This pattern is associated with a 30% lower risk of death and an 18% lower risk of cardiovascular events. This is particularly impactful in lower-income regions where these foods are less commonly consumed.

Mediterranean, DASH-style, pescetarian, and ovo/lacto-vegetarian dietary patterns, when implemented as intended, strongly align with 2021 AHA Dietary Guidance and support optimal cardiovascular health.

Adopt a Mediterranean, DASH, pescetarian, or vegetarian diet as your primary way of eating. Focus on vegetables, fruits, whole grains, and healthy fats like olive oil. If you eat animal products, choose lean meats, fish, or low-fat dairy. This approach is flexible, culturally adaptable, and strongly supported by heart health guidelines.

Tight blood-glucose control via traditional therapies does not significantly reduce macrovascular outcomes or heart failure risk in type 2 diabetes, whereas SGLT2 inhibitors and GLP-1 agonists significantly reduce cardiovascular mortality and heart failure hospitalization.

If you have Type 2 Diabetes and are at risk for heart issues, simply keeping your blood sugar numbers low with older medications may not protect your heart. Current guidelines recommend using specific newer medications (SGLT2 inhibitors or GLP-1 agonists) because they have proven to reduce the risk of heart failure and cardiovascular death, independent of their glucose-lowering effects. Discuss these specific classes with your doctor.

High-quality carbohydrate diets (emphasizing whole grains, pulses, fruit, low glycemic index/load, and high viscous fiber) decrease intermediate cardiometabolic risk factors and are associated with reduced incidence of diabetes, cardiovascular disease, and mortality, whereas low-carbohydrate diets show no long-term superiority for weight loss or sustained glycemic control.

Focus on the quality of carbohydrates rather than restricting their quantity. Prioritize whole grains (especially oats and barley), pulses, fruit, and high-fiber foods. Limit sugar-sweetened beverages. This approach is associated with better long-term weight management and reduced risk of diabetes and heart disease compared to low-carbohydrate diets.

Second-generation anti-obesity medications (semaglutide 2.4 mg and tirzepatide) induce significantly greater weight loss (15-21%) compared to traditional lifestyle modification (5-10%) by pharmacologically enhancing satiation and reducing hunger, thereby decreasing the reliance on cognitive behavioral strategies for calorie restriction.

If you have obesity, second-generation medications like semaglutide or tirzepatide are significantly more effective than lifestyle changes alone, producing 15-21% weight loss compared to 5-10%. They work by reducing hunger and increasing fullness, which reduces the mental effort needed to restrict calories. While they require weekly injections and gradual dose titration to manage side effects, they represent a major advancement in obesity treatment.

Dietary guidelines should prioritize overall diet quality and minimally processed foods over isolated nutrient targets (such as total fat or calories) to effectively prevent chronic disease and obesity.

Stop obsessing over single nutrients like total fat or strict calorie counting. Instead, build your diet around minimally processed, nutrient-dense foods like vegetables, fruits, nuts, seeds, beans, whole grains, and healthy oils. Actively avoid ultra-processed foods high in refined sugars, starches, and industrial additives like trans fats.

Tirzepatide, a dual GIP/GLP-1 receptor agonist administered via once-weekly subcutaneous injections, significantly improves glycemic control and reduces body weight in patients with type 2 diabetes and obesity compared to placebo, GLP-1 agonists, and basal insulin.

Tirzepatide is a once-weekly injection that activates two gut hormones (GIP and GLP-1) to help your pancreas release insulin when needed, slow down digestion, and reduce appetite. It is prescribed for type 2 diabetes and obesity. Clinical trials show it lowers blood sugar and body weight more effectively than many existing diabetes and weight-loss medications. Common side effects include nausea and diarrhea, which usually improve over time. It is taken alongside diet and exercise changes.